Key result
Novel biomarkers, including non-coding RNAs and markers of cardiac fibrosis and inflammation, are being investigated to overcome the low specificity of standard biomarkers like BNP for post-MI heart failure.
Why the study?
Heart failure is a frequent and high-mortality complication following myocardial infarction, highlighting the need for appropriate biomarkers for diagnosis, prognosis, and treatment.
Do novel biomarkers improve the diagnosis and prognosis of heart failure after myocardial infarction compared to standard biomarkers?
Systematic Review (n=20)
Do novel biomarkers improve the diagnosis and prognosis of heart failure after myocardial infarction compared to standard biomarkers?
Standard biomarkers have limitations in specificity for post-MI heart failure, highlighting the potential utility of novel biomarkers including non-coding RNAs, inflammatory, and fibrosis markers.
Answers are grounded in this paper and cite their sources.
Clinicians should interpret post-MI BNP/NT-proBNP results cautiously given limited specificity; systematic evidence leaves open the added value of novel biomarkers pending validation.
Heart failure (HF) after a myocardial infarction (MI) is one of the most frequent complications and with the highest mortality rate in the population. Given this, the importance of finding appropriate biomarkers for the diagnosis, prognosis and treatment of this condition. The review was carried out under an analytical approach, using the PRISMA statement as a methodology; for this, documents were retrieved through the Scopus, ScienceDirect and PubMed databases, where 20 articles that met certain inclusion criteria were recognized. In conclusion, it was explained that the use of standard biomarkers such as B-type natriuretic peptide (BNP) and non-terminal pro-BNP in clinical practice have limitations, especially due to their low specificity for HF as a post-MI complication. Therefore, currently, biomarkers that reflect the alteration of cardiac integrity, biomarkers of cardiac injury and necrosis, inflammatory biomarkers, biomarkers of cardiac fibrosis, biomarkers of biomechanical myocardial stress, and other types of biomarkers such as non-coding RNAs are being investigated
No takes yet. Share an insight, caveat, or question.
Vásquez-Donet et al. (2023) conducted a systematic review in Heart failure post-myocardial infarction (n=20). Novel biomarkers (non-coding RNAs, inflammatory, fibrosis, and cardiac injury markers) vs. Standard biomarkers (BNP, NT-proBNP) was evaluated on Utility of biomarkers for diagnosis and prognosis of post-MI heart failure. Novel biomarkers, including non-coding RNAs and markers of cardiac fibrosis and inflammation, are being investigated to overcome the low specificity of standard biomarkers like BNP for post-MI heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: